Drugs / BB102
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06258408 | Dec 2022 → Dec 2026 expected | neoplasm | Broadenbio Ltd., Co. | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07239986 | Dec 2025 → Jun 2027 expected | hepatocellular carcinoma | Broadenbio Ltd., Co. | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-04-22 | Broadenbio Ltd., Co. | Results 新一代FGFR4降解剂BB102——肝癌治疗新希望 broadenbio.com ↗
在4月21日的2026年美国肿瘤年会（AACR）上，伯汇生物首次报道了BB102作为FGFR4降解剂的作用机制及临床前研究结果。 |
| 2024-04-07 | Broadenbio Ltd., Co. | Results 伯汇生物两项临床前研究成果入选AACR 2024年会壁报展示 broadenbio.com ↗
在体外和体内实验中，BB102显著抑制多种实体瘤的增长，并能有效降低肿瘤组织中FGFR4的表达。 |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-04-22 | Broadenbio Ltd., Co. | 新一代FGFR4降解剂BB102——肝癌治疗新希望 broadenbio.com ↗ |
| 2024-04-07 | Broadenbio Ltd., Co. | 伯汇生物两项临床前研究成果入选AACR 2024年会壁报展示 broadenbio.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BB102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07239986 ↗ |
| Action | Inhibit | “a highly selective and potent FGFR4 inhibitor” NCT06258408 ↗ |
| Route | Oral | “BB102 tablets will be administered orally once daily(QD).” NCT06258408 ↗ |
| Target | FGFR4 | “a highly selective and potent FGFR4 inhibitor” NCT06258408 ↗ |